Personalized oncology DNAmito offers a clinical-grade decision support system (PRODECIS) that personalizes cancer treatment planning using genomics and multi-factor data, presenting a compelling value proposition for oncology clinics seeking tailored therapies and improved outcomes.

Genomics driven MITOTx aims to provide saliva-based SNP and mitochondrial DNA testing to assess radiation toxicity risk, creating an opportunity to upsell pre-treatment genomic screening services to radiation oncology departments.

Cost-effectiveness PRODECIS incorporates toxicity, tumor control, quality of life, and cost-effectiveness in its models, which can be positioned to hospital buyers as a tool to optimize treatment plans while reducing waste and potentially lowering overall costs.

Small team, niche With a lean 2-10 employee footprint and a specialized product set, DNAmito can pursue targeted pilot programs or clinical collaborations with select cancer centers, accelerating case studies and reference wins.

Expansion potential The company’s health tech stack and focus on genomics-based decision support align with trends toward precision medicine in radiation oncology, suggesting opportunities to partner with large health systems, CROs, or EMR-integrated vendors for broader adoption.